Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Heart and Vessels

Volumn 31, Issue 8, 2016, Pages 1327-1336

  Miyamoto, Koji ^a,b   Aiba, Takeshi ^a   Arihiro, Shoji ^a   Watanabe, Makoto ^a   Kokubo, Yoshihiro ^a   Ishibashi, Kohei ^a   Hirose, Sayako ^a   Wada, Mitsuru ^a   Nakajima, Ikutaro ^a   Okamura, Hideo ^a,b   Noda, Takashi ^a   Nagatsuka, Kazuyuki ^a   Noguchi, Teruo ^a   Anzai, Toshihisa ^a,b   Yasuda, Satoshi ^a,b   Ogawa, Hisao ^a,b   Kamakura, Shiro ^a   Shimizu, Wataru ^a,b,c   Miyamoto, Yoshihiro ^a   Toyoda, Kazunori ^a   Kusano, Kengo ^a,b   more..

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Atrial fibrillation; CHA2DS2 VASc score; CHADS2 score; Non vitamin K antagonist oral anticoagulants; Renal function

Indexed keywords

APIXABAN; CREATININE; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT;

AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BODY WEIGHT; BRAIN HEMORRHAGE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG WITHDRAWAL; ESTIMATED CREATININE CLEARANCE; FEMALE; FOLLOW UP; HUMAN; JAPANESE (PEOPLE); KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON VALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; UNSPECIFIED SIDE EFFECT; BLOOD; CHEMICALLY INDUCED; HEMORRHAGE; INCIDENCE; JAPAN; KAPLAN MEIER METHOD; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CREATININE; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84939246848     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-015-0725-6     Document Type: Article

References (35)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKETAF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992
4. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M, J-ROCKET AF study investigators (2012) Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J 76:2104–2111
5. Miyamoto K, Aiba T, Nakajima I, Yamada Y, Okamura H, Noda T, Satomi K, Ishihara M, Anzai T, Yasuda S, Ogawa H, Kamakura S, Shimizu W (2014) Efficacy and safety of novel anticoagulant dabigatran in clinical practice for japanese patients with non-valvular atrial fibrillation. J Arrhythm 30:58–64
6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104
7. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L (2014) Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation, A RE-LY trial analysis. Circulation 129:961–970
8. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363–2372
9. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KA, Califf RM, ROCKETAF Investigators (2014) Factors associated with major bleeding events: insights from the rivaroxaban once-daily oral direct factor Xa Inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). J Am Coll Cardiol 63:891–900
10. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33:2821–2830
11. 2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127:224–232
12. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY (2013) Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 34(46):3572–3579
13. Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM, Lip GY (2013) Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 61:2079–2087
14. Kdigo, CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150
15. Japan nephrology society (2012) Special issue: clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai Shi 54(8):1034–1191
16. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–272
18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100
19. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113:671–678
20. Tanaka H, Ueda Y, Hayashi M, Date C, Baba T, Yamashita H, Shoji H, Tanaka Y, Owada K, Detels R (1982) Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 13:62–73
21. Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, Higashiyama A, Kamide K, Kawanishi K, Okayama A, Kawano Y (2009) Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. Stroke 40:2674–2679
22. Ohara T, Kokubo Y, Toyoda K, Watanabe M, Koga M, Nakamura S, Nagatsuka K, Minematsu K, Nakagawa M, Miyamoto Y (2013) Impact of chronic kidney disease on carotid atherosclerosis according to blood pressure category: the Suita Study. Stroke 44:3537–3539
23. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
24. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J (2004) The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140:9–17
25. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM (2003) Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87–92
26. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, van Ryn J, Veltkamp R (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42:3594–3599
27. Lin TH, Lai WT, Kuo CT, Hwang JJ, Chiang FT, Chang SC, Chang CJ (2014) Additive effect of in-hospital TIMI bleeding and chronic kidney disease on 1-year cardiovascular events in patients with acute coronary syndrome: data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. Heart Vessels. doi:10.1007/s00380-014-0504-9
28. Guenancia C, Stamboul K, Hachet O, Yameogo V, Garnier F, Gudjoncik A, Cottin Y, Lorgis L (2015) Clinical effectiveness of the systematic use of the GRACE scoring system (in addition to clinical assessment) for ischemic outcomes and bleeding complications in the management of NSTEMI compared with clinical assessment alone: a prospective study. Heart Vessels. doi:10.1007/s00380-015-0695-8
29. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD (1992) Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 268:3085–3091
30. Poggio ED, Rule AD, Tanchanco R, Arrigain S, Butler RS, Srinivas T, Stephany BR, Meyer KH, Nurko S, Fatica RA, Shoskes DA, Krishnamurthi V, Goldfarb DA, Gill I, Schreiber MJ Jr (2009) Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int 75:1079–1087
31. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393
32. Ronco C, Ronco F (2012) Cardio-renal syndromes: a systematic approach for consensus definition and classification. Heart Fail Rev 17:151–160
33. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A (2007) Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 71:159–166
34. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A (2011) Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9:2168–2175
35. Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, Vicente V, Lip GY (2013) Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 111:1159–1164